Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer
Phase 2
Terminated
NCT05167409
| Condition | Microsatellite Stable Metastatic Colorectal Cancer |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | University of Colorado, Denver |
|---|
| Status | Terminated |
|---|
| Enrollment | 19 participants |
|---|
| Interventions | Evorpacept (ALX148), Cetuximab, Pembrolizumab |
|---|
| Start date | Jul 28, 2022 |
|---|
| Completion date | Oct 30, 2024 |
|---|
| Results posted | Jul 22, 2026 |
|---|
Summary
This Phase 2 clinical study will evaluate evorpacept (ALX148) in combination with cetuximab and pembrolizumab for refractory microsatellite stable metastatic colorectal cancer
Objective Response Rate (ORR)
The duration of time during which tumor assessments were performed for each individual patient. Per protocol, assessments will continue until disease progression. The latest assessment was performed at Cycle 21, Day 15 (14.5 mo after informed consent) · Participants
| Experimental: Stage 1: Safety run-in Evaluating Evorpacept at 10 mg/kg Weekly | 0 Participants |
|---|
| Experimental: Stage 1: Safety run-in Evaluating Evorpacept at 15 mg/kg Weekly | 0 Participants |
|---|
| Experimental: Stage 2: Expansion Cohort Using Recommended Dose (RD) of Evorpacept | 1 Participants |
|---|
Determine the Recommended Dose (RD) of Evorpacept (ALX148) in Combination With Cetuximab and Pembrolizumab
During the safety run-in, each patient must have completed at least the 1st cycle (3 weeks) of treatment. · Participants
| Experimental: Stage 1: Safety run-in Evaluating Evorpacept at 10 mg/kg Weekly | 0 Participants |
|---|
| Experimental: Stage 1: Safety run-in Evaluating Evorpacept at 15 mg/kg Weekly | 1 Participants |
|---|
| Experimental: Stage 2: Expansion Cohort Using Recommended Dose (RD) of Evorpacept | 0 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.